Acquired aplastic anemia: recent advances in pathophysiology and treatment

DOI Web Site PubMed

Bibliographic Information

Other Title
  • 再生不良性貧血
  • 再生不良性貧血 : 最新の病態解析と治療法の進展
  • サイセイ フリョウセイ ヒンケツ : サイシン ノ ビョウタイ カイセキ ト チリョウホウ ノ シンテン
  • —最新の病態解析と治療法の進展—

Search this article

Abstract

<p>Acquired aplastic anemia (AA) is an autoimmune disease caused by T cells specific to hematopoietic stem cells (HSCs). The presence of HLA allele-lacking leukocytes due to uniparental disomy of the short arm of chromosome 6 (6pUPD) or allelic mutations strongly indicates the involvement of such cytotoxic T cells in the pathogenesis of AA. Attempts to improve treatment outcomes by intensification of immunosuppressive therapy (IST) have been unsuccessful. Eltrombopag (EPAG), a thrombopoietin receptor agonist, has recently emerged as a novel therapeutic agent for AA. EPAG directly acts on HSCs and stimulates proliferation, thereby achieving remission in approximately 40% AA patients refractory to IST. However, some cases develop chromosomal aberrations during treatment. Because somatic mutations are common in patients with AA, verifying whether EPAG induces clonal proliferation or evolution of mutant HSCs is critical.</p>

Journal

  • Rinsho Ketsueki

    Rinsho Ketsueki 59 (6), 711-715, 2018

    The Japanese Society of Hematology

Related Projects

See more

Keywords

Details 詳細情報について

Report a problem

Back to top